TELA Bio (NASDAQ:TELA) Price Target Lowered to $12.00 at Piper Sandler

TELA Bio (NASDAQ:TELAFree Report) had its price objective reduced by Piper Sandler from $15.00 to $12.00 in a report issued on Friday morning, Benzinga reports. They currently have an overweight rating on the stock.

Separately, Lake Street Capital restated a buy rating and issued a $14.00 price objective on shares of TELA Bio in a report on Wednesday, December 27th.

Read Our Latest Report on TELA Bio

TELA Bio Trading Up 7.1 %

NASDAQ TELA opened at $5.73 on Friday. TELA Bio has a 52 week low of $4.23 and a 52 week high of $11.65. The business’s fifty day simple moving average is $6.66 and its 200-day simple moving average is $6.54. The company has a current ratio of 5.36, a quick ratio of 4.43 and a debt-to-equity ratio of 1.32.

Institutional Trading of TELA Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC increased its stake in TELA Bio by 3.0% during the fourth quarter. First Light Asset Management LLC now owns 2,554,641 shares of the company’s stock worth $16,912,000 after purchasing an additional 74,377 shares during the period. AIGH Capital Management LLC grew its position in shares of TELA Bio by 10.0% during the fourth quarter. AIGH Capital Management LLC now owns 1,377,945 shares of the company’s stock worth $9,122,000 after buying an additional 125,000 shares in the last quarter. Nantahala Capital Management LLC grew its position in shares of TELA Bio by 140.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,097,866 shares of the company’s stock worth $7,268,000 after buying an additional 641,774 shares in the last quarter. BlackRock Inc. boosted its holdings in TELA Bio by 5,349.1% in the second quarter. BlackRock Inc. now owns 1,011,523 shares of the company’s stock valued at $10,247,000 after purchasing an additional 992,960 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in TELA Bio by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 998,853 shares of the company’s stock valued at $6,612,000 after purchasing an additional 22,850 shares in the last quarter. 91.06% of the stock is currently owned by hedge funds and other institutional investors.

TELA Bio Company Profile

(Get Free Report)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Recommended Stories

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.